Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3,155 INR
Change Today -45.05 / -1.41%
Volume 7.2K
As of 7:06 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi india ltd (SANL) Snapshot

Open
3,200
Previous Close
3,200
Day High
3,200
Day Low
3,086
52 Week High
11/21/14 - 3,788
52 Week Low
08/11/14 - 2,722
Market Cap
72.7B
Average Volume 10 Days
23.1K
EPS TTM
63.00
Shares Outstanding
23.0M
EX-Date
04/16/15
P/E TM
50.1x
Dividend
34.00
Dividend Yield
1.43%
Current Stock Chart for SANOFI INDIA LTD (SANL)

Related News

No related news articles were found.

sanofi india ltd (SANL) Related Businessweek News

No Related Businessweek News Found

sanofi india ltd (SANL) Details

Sanofi India Limited manufactures and sells pharmaceutical products in India and internationally. It provides medicines for the treatment of patients in various therapeutic areas, such as cardiology, thrombosis, oncology, diabetes, central nervous system, internal medicine, and consumer healthcare. The company also offers medicines for the treatment of respiratory systems, dermatology, analgesics, anti-infectives, bone and joint diseases, and gastrointestinal disorders. It primarily provides its products under the brand names of Cardace, Lantus, Insuman, Apidra, All Star, Amaryl, Cetapin, Clexane, Targocid, Allegra, Taxotere, Combiflam Plus, Novalgin NU, Baralgin NU, Seacod, Avil, and Enlarge Forte. The company was incorporated in 1956 and is based in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

3,448 Employees
Last Reported Date: 03/9/15
Founded in 1956

sanofi india ltd (SANL) Top Compensated Officers

Managing Director, Vice President of South As...
Total Annual Compensation: 8.6M
Chief Financial Officer, Whole-Time Director,...
Total Annual Compensation: 6.1M
Senior Director of Industrial Affairs - India
Total Annual Compensation: 9.8M
Compensation as of Fiscal Year 2013.

sanofi india ltd (SANL) Key Developments

Sanofi India Limited Announces Change in Registered Office Address

Sanofi India Limited announced the registered office of the company has been shifted from 54/A, Sir Mathuradas Vasanji Road, Andheri East, Mumbai-40093 to Sanofi House, 117-B, L&T Business park, Saki Vihar Road, Powai, Mumbai-400072.

Sanofi India Limited Recommends Final Dividend and Special Dividend for the Year Ended December 31, 2014

Sanofi India Limited announced that the board of directors of the company at their meeting held on February 20, 2015, the board has recommended final dividend of INR 24 per equity share of INR 10 for the year ended December 31, 2014. An Interim dividend of INR 10 per equity share of INR 10 had been paid in August 2014. A Special One-time dividend of INR 11 per equity shares of INR 10 arising from the profit on the sale of the company's commercial premises in Mumbai.

Sanofi India Limited Announces Audited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Sanofi India Limited announced audited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales of INR 4,811 million compared with INR 4,611 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 315 million compared with INR 900 million for the same period a year ago. Profit before tax and exceptional items was INR 466 million compared with INR 1,018 million for the same period a year ago. Net profit after exceptional items was INR 925 million or INR 40.09 per diluted share before and after extraordinary items compared with INR 927 million or INR 40.29 per diluted share before and after extraordinary items for the same period a year ago. For the year, the company reported net sales of INR 18,750 million compared with INR 17,065 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 2,423 million compared with INR 3,056 million for the same period a year ago. Profit before tax and exceptional items was INR 3,061 million compared with INR 3,631 million for the same period a year ago. Net profit after exceptional items was INR 2,637 million or INR 114.46 per diluted share before and after extraordinary items compared with INR 2,652 million or INR 115.15 per diluted share before and after extraordinary items for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANL:IN 3,154.85 INR -45.05

SANL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott India Ltd 3,900 INR +26.50
Cadila Healthcare Ltd 1,702 INR -65.70
Medivation Inc $126.62 USD -4.39
Pfizer Ltd/India 2,046 INR -103.40
Piramal Enterprises Ltd 935.35 INR -14.60
View Industry Companies
 

Industry Analysis

SANL

Industry Average

Valuation SANL Industry Range
Price/Earnings 36.9x
Price/Sales 3.7x
Price/Book 4.9x
Price/Cash Flow 20.2x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI INDIA LTD, please visit www.sanofiindialtd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.